Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

By E. Swisher, K. Lin, A. Oza, C. Scott, H. Giordano, James X. Sun, G. Konecny, R. Coleman, A. Tinker, D. O’Malley and 21 more. The Lancet Oncology, 2017

1,057 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/c6bde5a344444818c1f73cce6aa844d3d7aa60f6